Table 4.
Response to bDMARDs in obese/overweight patients with spondyloarthritis.
| Author (Reference) | Number of Subjects | Disease | Sex Ratio M/F (%) | Disease Duration (Years) | Obese/Overweight Subjects (%) | bDMARDs | Outcome | Main Results |
|---|---|---|---|---|---|---|---|---|
| Ottaviani [70] | 155 | AS | 63.3/36.7 | 8 | overweight: 35 obese: 25 |
IFX (5 mg/kg) | BASDAI50 at month 6 | Fewer responders in obese/overweight groups |
| Gremese [71] | 170 | ax-SpA | 69.4/ 30.6 | 16.3 | overweight: 32.4 obese: 13.5 |
IFX (5 mg/kg) or ETA or ADA | BASDAI 50 month 6 | Rate of responders lower in obese and overweight patients |
| Micheroli [72] | 624 | ax-SpA | 62.2/ 37.8 | 13 | overweight: 32.7 obese: 14.1 |
all TNFi | Rate of ASAS40 responders at one year | Rate of responders lower in obese and overweight patients |
| Ibanez Vodnizza [73] | 41 | AS | 61/39 | 14.6 | overweight: 36.6 obese: 12.2 |
ETA or ADA | BASDAI or ASDAS-CRP change at month 6 | Higher body fat associated with worse response to TNFi |
| Di Minno [74] | 270 | PsA | 62/38 | 9.2 | obese: 50 | IFX (5 mg/kg) ETA or ADA |
MDA at month 12 | Rate of MDA < obese patients vs non obese |
| Iannone [75] | 135 | PsA | 50.4/49.6 | ND | overweight: 34.8 obese: 33 |
IFX (5 mg/kg) ETA or ADA |
DAS28 or SDAI response | No difference in rate of remission according to DAS28 or SDAI |
| Eder [76] | 557 | PsA | 58.4/41.6 | 15 | overweight: 36.2 obese: 35.4 |
TNFi without precision | MDA at month 12 | Less MDA in obese category |
| Hojgaard [77] | 1943 | PsA | 44.5/55.5 | 4 | obese: 34.6 | all TNFi | EULAR response at month 6 | EULAR response lower in the obese category |
| Mc Innes [83] | 422 | PsA | female % according to BMI categories: - placebo: 41% to 64% abatacept: 42.9 to 67.7% |
NA | Placebo group: overweight: 27.1% obese: 54.3% Abatacept group: overweight: 36.3% obese: 49% |
abatacept SC | ACR20 | no difference in the rate of responders between obese/overweight and normal weight patients |
(TNF inhibitor, IL-23 inhibitor and IL-17A inhibitor) in axial spondyloarthritis and psoriatic arthritis according to body weight or body mass index (M: male; F: female; BMI: body mass index; bDMARD: biological disease-modifying antirheumatic drug; TNFi: TNF inhibitor; IFX: infliximab; ETA: etanercept; ADA: adalimumab; AS: ankylosing spondylitis; SpA: spondyloarthritis; ax-SpA: axial spondyloarthritis; PsA: psoriatic arthritis; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ASAS: Assessment of SpondyloArthritis Society; EULAR: European League Against Rheumatism; MDA: minimal disease activity; ACR: American College of Rhematology; NA: not available).